138 related articles for article (PubMed ID: 22037226)
21. Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study.
Park JY; Kim CW; Bae SH; Jung KS; Kim HY; Yoon SK; Han KH; Ahn SH
Liver Int; 2016 Aug; 36(8):1108-15. PubMed ID: 26781724
[TBL] [Abstract][Full Text] [Related]
22. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B.
Mauss S; Berger F; Filmann N; Hueppe D; Henke J; Hegener P; Athmann C; Schmutz G; Herrmann E
J Hepatol; 2011 Dec; 55(6):1235-40. PubMed ID: 21703180
[TBL] [Abstract][Full Text] [Related]
23. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.
Chevaliez S; Hézode C; Bahrami S; Grare M; Pawlotsky JM
J Hepatol; 2013 Apr; 58(4):676-83. PubMed ID: 23219442
[TBL] [Abstract][Full Text] [Related]
24. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.
Liaw YF; Sheen IS; Lee CM; Akarca US; Papatheodoridis GV; Suet-Hing Wong F; Chang TT; Horban A; Wang C; Kwan P; Buti M; Prieto M; Berg T; Kitrinos K; Peschell K; Mondou E; Frederick D; Rousseau F; Schiff ER
Hepatology; 2011 Jan; 53(1):62-72. PubMed ID: 21254162
[TBL] [Abstract][Full Text] [Related]
25. Clinical and virological response to entecavir in HBV-related chronic hepatitis or cirrhosis: data from the clinical practice in a single-centre cohort.
Marengo A; Bitetto D; D'Avolio A; Ciancio A; Fabris C; Marietti M; Toniutto P; Di Perri G; Rizzetto M; Marzano A
Antivir Ther; 2013; 18(1):87-94. PubMed ID: 22872649
[TBL] [Abstract][Full Text] [Related]
26. Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia.
Childs K; Joshi D; Byrne R; Bruce M; Carey I; Agarwal K; Taylor C
AIDS; 2013 Jun; 27(9):1443-8. PubMed ID: 23435302
[TBL] [Abstract][Full Text] [Related]
27. Low hepatitis B envelope antigen seroconversion rate in chronic hepatitis B patients on long-term entecavir 0.5 mg daily in routine clinical practice.
Liu A; Ha NB; Lin B; Yip B; Trinh HN; Nguyen HA; Nguyen KK; Ahmed A; Garcia G; Nguyen MH
Eur J Gastroenterol Hepatol; 2013 Mar; 25(3):338-43. PubMed ID: 23169311
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a ‘real-world’ clinical practice setting in China.
Hou JL; Jia JD; Wei L; Zhao W; Wang YM; Cheng M; Tang X; Tan DM; Ren H; Tang H; Cohen D; Llamoso C
J Viral Hepat; 2013 Nov; 20(11):811-20. PubMed ID: 23876210
[TBL] [Abstract][Full Text] [Related]
29. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study.
Tsai MC; Chen CH; Hung CH; Lee CM; Chiu KW; Wang JH; Lu SN; Tseng PL; Chang KC; Yen YH; Hu TH
Clin Microbiol Infect; 2014 Feb; 20(2):O90-O100. PubMed ID: 23659493
[TBL] [Abstract][Full Text] [Related]
30. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis.
Zoutendijk R; Reijnders JG; Zoulim F; Brown A; Mutimer DJ; Deterding K; Hofmann WP; Petersen J; Fasano M; Buti M; Berg T; Hansen BE; Sonneveld MJ; Wedemeyer H; Janssen HL;
Gut; 2013 May; 62(5):760-5. PubMed ID: 22490523
[TBL] [Abstract][Full Text] [Related]
31. Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study.
Ahn J; Lee HM; Lim JK; Pan CQ; Nguyen MH; Ray Kim W; Mannalithara A; Trinh H; Chu D; Tran T; Min A; Do S; Te H; Reddy KR; Lok AS
Aliment Pharmacol Ther; 2016 Jan; 43(1):134-44. PubMed ID: 26510638
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma.
Riveiro-Barciela M; Tabernero D; Calleja JL; Lens S; Manzano ML; Rodríguez FG; Crespo J; Piqueras B; Pascasio JM; Comas C; Gutierrez ML; Aguirre A; Suárez E; García-Samaniego J; Rivero M; Acero D; Fernandez-Bermejo M; Moreno D; Sánchez-Pobre P; de Cuenca B; Moreno-Palomares JJ; Esteban R; Buti M
Dig Dis Sci; 2017 Mar; 62(3):784-793. PubMed ID: 28078526
[TBL] [Abstract][Full Text] [Related]
33. Comparison of tenofovir and entecavir in patients with chronic HBV infection.
Ceylan B; Yardimci C; Fincanci M; Eren G; Tozalgan U; Muderrisoglu C; Akkoyunlu Y
Eur Rev Med Pharmacol Sci; 2013 Sep; 17(18):2467-73. PubMed ID: 24089225
[TBL] [Abstract][Full Text] [Related]
34. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment.
Wong GL; Chan HL; Chan HY; Tse PC; Tse YK; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Wong VW
Gastroenterology; 2013 May; 144(5):933-44. PubMed ID: 23415803
[TBL] [Abstract][Full Text] [Related]
35. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure.
Garg H; Sarin SK; Kumar M; Garg V; Sharma BC; Kumar A
Hepatology; 2011 Mar; 53(3):774-80. PubMed ID: 21294143
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of long-term entecavir therapy in a European population.
Collo A; Belci P; Fagoonee S; Loreti L; Gariglio V; Parise R; Magistroni P; Durazzo M
Minerva Gastroenterol Dietol; 2018 Sep; 64(3):201-207. PubMed ID: 29327822
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of tenofovir, entecavir, and telbivudine for chronic hepatitis B in heart transplant recipients.
Durante-Mangoni E; Vitrone M; Parrella A; Andini R; Iossa D; Ragone E; Falco E; Maiello C; Utili R; Zampino R
Transpl Infect Dis; 2016 Jun; 18(3):319-25. PubMed ID: 26988401
[TBL] [Abstract][Full Text] [Related]
38. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis.
Wong GL; Chan HL; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Lai JW; Lo AO; Chan HY; Wong VW
Hepatology; 2013 Nov; 58(5):1537-47. PubMed ID: 23389810
[TBL] [Abstract][Full Text] [Related]
39. Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.
Goyal SK; Dixit VK; Shukla SK; Ghosh J; Behera M; Tripathi M; Gupta N; Ranjan A; Jain AK
Indian J Gastroenterol; 2015 Jul; 34(4):286-91. PubMed ID: 26243587
[TBL] [Abstract][Full Text] [Related]
40. The effect of long-term entecavir therapy on liver histopathology in patients with chronic viral hepatitis B.
Kose S; Tatar B; Gül S; Pala E
Acta Clin Belg; 2016 Aug; 71(4):244-9. PubMed ID: 27075801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
